Barclays PLC Vanda Pharmaceuticals Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

A detailed history of Barclays PLC transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Barclays PLC holds 154,297 shares of VNDA stock, worth $745,254. This represents 0.0% of its overall portfolio holdings.

Number of Shares
154,297
Previous 154,297 -0.0%
Holding current value
$745,254
Previous $722,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$4.61 - $6.34 $399,580 - $549,532
86,677 Added 128.18%
154,297 $722,000
Q2 2024

Aug 14, 2024
SELL
$3.91 - $6.5 $226,998 - $377,364
-58,056 Reduced 46.19%
67,620 $382,000
Q1 2024

May 15, 2024
SELL
$3.47 - $4.61 $159,488 - $211,884
-45,962 Reduced 26.78%
125,676 $516,000
Q4 2023

Feb 15, 2024
BUY
$3.38 - $4.58 $146,381 - $198,350
43,308 Added 33.75%
171,638 $725,000
Q3 2023

Nov 07, 2023
BUY
$4.28 - $6.57 $13,974 - $21,451
3,265 Added 2.61%
128,330 $554,000
Q2 2023

Aug 03, 2023
BUY
$5.9 - $6.95 $146,148 - $172,158
24,771 Added 24.7%
125,065 $824,000
Q1 2023

May 04, 2023
BUY
$6.18 - $7.99 $21,939 - $28,364
3,550 Added 3.67%
100,294 $682,000
Q4 2022

Feb 13, 2023
SELL
$6.87 - $10.96 $17,573 - $28,035
-2,558 Reduced 2.58%
96,744 $716,000
Q3 2022

Nov 03, 2022
BUY
$9.44 - $11.76 $765,055 - $953,077
81,044 Added 443.88%
99,302 $981,000
Q2 2022

Aug 12, 2022
SELL
$9.31 - $11.84 $246,817 - $313,890
-26,511 Reduced 59.22%
18,258 $199,000
Q1 2022

May 16, 2022
SELL
$10.84 - $16.55 $291,292 - $444,731
-26,872 Reduced 37.51%
44,769 $507,000
Q4 2021

Feb 14, 2022
BUY
$15.69 - $21.14 $232,823 - $313,696
14,839 Added 26.12%
71,641 $1.12 Million
Q3 2021

Nov 09, 2021
BUY
$15.35 - $21.27 $351,699 - $487,338
22,912 Added 67.61%
56,802 $974,000
Q2 2021

Aug 13, 2021
SELL
$15.71 - $21.51 $1 Million - $1.37 Million
-63,808 Reduced 65.31%
33,890 $729,000
Q1 2021

May 13, 2021
BUY
$13.42 - $20.28 $205,446 - $310,466
15,309 Added 18.58%
97,698 $1.47 Million
Q4 2020

Feb 11, 2021
SELL
$9.77 - $13.81 $243,468 - $344,145
-24,920 Reduced 23.22%
82,389 $1.08 Million
Q3 2020

Nov 12, 2020
BUY
$9.32 - $12.02 $95,716 - $123,445
10,270 Added 10.58%
107,309 $1.04 Million
Q2 2020

Aug 12, 2020
BUY
$9.66 - $12.02 $228,845 - $284,753
23,690 Added 32.3%
97,039 $1.11 Million
Q1 2020

May 13, 2020
SELL
$7.5 - $16.8 $123,315 - $276,225
-16,442 Reduced 18.31%
73,349 $760,000
Q4 2019

Feb 10, 2020
BUY
$12.38 - $17.47 $175,981 - $248,336
14,215 Added 18.81%
89,791 $1.47 Million
Q3 2019

Nov 14, 2019
SELL
$12.27 - $15.79 $184,553 - $237,497
-15,041 Reduced 16.6%
75,576 $1 Million
Q2 2019

Aug 14, 2019
BUY
$13.37 - $18.85 $309,221 - $435,962
23,128 Added 34.27%
90,617 $1.28 Million
Q1 2019

May 15, 2019
BUY
$17.59 - $31.05 $769,632 - $1.36 Million
43,754 Added 184.34%
67,489 $1.24 Million
Q4 2018

Feb 14, 2019
SELL
$18.97 - $31.47 $787,198 - $1.31 Million
-41,497 Reduced 63.61%
23,735 $620,000
Q3 2018

Nov 14, 2018
BUY
$18.25 - $23.0 $1.07 Million - $1.35 Million
58,631 Added 888.21%
65,232 $1.5 Million
Q2 2018

Aug 14, 2018
SELL
$13.95 - $19.15 $253,150 - $347,515
-18,147 Reduced 73.33%
6,601 $126,000
Q1 2018

May 15, 2018
BUY
$14.05 - $20.2 $167,195 - $240,380
11,900 Added 92.62%
24,748 $417,000
Q4 2017

Feb 14, 2018
SELL
$12.85 - $18.1 $474,679 - $668,614
-36,940 Reduced 74.19%
12,848 $195,000
Q3 2017

Nov 14, 2017
BUY
$15.4 - $18.85 $766,735 - $938,503
49,788
49,788 $891,000

Others Institutions Holding VNDA

# of Institutions
161
Shares Held
45.2M
Call Options Held
165K
Put Options Held
33.6K
View Full List

About Vanda Pharmaceuticals Inc.

VNDA Quotes by TradingView
  • Ticker VNDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,561,500
  • Market Cap $273M
  • Description
  • Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...
More about VNDA
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email